Accordingly, we discovered higher levels of β-catenin and Wnt-1 in the OSCC group compared to the sham group; however, a significant decrease in their levels was been demonstrated following GSK343 treatment, confirming the direct involvement of EZH2 in Wnt/β-catenin pathway activation in oral cancer. This evidence concerns the gene EZH2 and lip and oral cavity carcinoma.